A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial
NCT02712489 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 179
Last updated 2016-12-29
Summary
A roll-over observational study (ISS T-003 EF-UP) is being conducted to extend the follow-up of the volunteers of the ISS T-003 trial in order to evaluate the persistence of vaccine immunogenicity as well as of the immunological and virological effects induced by the therapeutic immunization with Tat.
Conditions
- HIV Infections
Interventions
- OTHER
-
No intervention
Sponsors & Collaborators
-
Italian Ministry of Foreign Affairs - General Direction for Cooperation and Development
collaborator UNKNOWN -
Barbara Ensoli, MD, PhD
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-31
- Primary Completion
- 2016-04-30
- Completion
- 2016-10-31
Countries
- South Africa
More Related Trials
-
Observational Study for the Evaluation of the Role of HIV-1 Tat Protein and Anti-Tat Immune Response In HIV Reservoir
NCT04263207 ·Status: SUSPENDED
-
Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL)
NCT00301561 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy
NCT02097381 ·Status: UNKNOWN ·Phase: NA
-
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
NCT01213316 ·Status: COMPLETED
-
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
NCT01019551 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
NCT01252940 ·Status: COMPLETED ·Phase: PHASE3
-
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
NCT02121795 ·Status: COMPLETED ·Phase: PHASE3
-
Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults
NCT00820118 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
NCT01286740 ·Status: COMPLETED ·Phase: PHASE2
-
Rosuvastatin to Decrease Residual Immune Activation in HIV Infection
NCT01874743 ·Status: UNKNOWN ·Phase: PHASE2
-
Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults
NCT00343941 ·Status: COMPLETED ·Phase: PHASE2
-
Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)
NCT05312918 ·Status: UNKNOWN
-
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
NCT01968551 ·Status: COMPLETED ·Phase: PHASE3
-
Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa
NCT04066036 ·Status: COMPLETED
-
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
NCT00980538 ·Status: COMPLETED ·Phase: PHASE3
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01475838 ·Status: COMPLETED ·Phase: PHASE3
-
Switching From PI to RALtegravir in HIV Stable Patients
NCT00528892 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence
NCT01509508 ·Status: COMPLETED ·Phase: NA
-
Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial
NCT06485154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART)
NCT00122551 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
NCT01967940 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
NCT03227861 ·Status: COMPLETED ·Phase: PHASE3
-
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
NCT04644029 ·Status: TERMINATED ·Phase: PHASE3
-
Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens
NCT00627055 ·Status: COMPLETED ·Phase: PHASE4